Blockchain Papers

Follow blockchain research across journals, conferences, and preprint repositories.

31 papersLast indexed Aug 31, 2026
Search papers

Paper index

31 results ¡ page 2 of 2

Clear filters
Sep 24, 2009¡New England Journal of Medicine
1 cites
Poor Substitutes — Why Cooperatives and Triggers Can't Achieve the Goals of a Public Option

Jacob S. Hacker

According to a recent survey, a majority of U.S. physicians support health care reform that includes a new national public health insurance plan, which would compete with private plans.1 Polls have shown that a substantial majority of Americans support the public option as well.Yet the idea has occasioned considerable controversy on Capitol Hill. Senate Finance Committee chairman Max Baucus (D-MT) recently unveiled his draft bill (the chairman's “mark”), which contains no competing public plan. Instead, it substitutes the largely untested idea of providing federal loans and start-up funds to encourage the creation of decentralized, member-run health care “cooperatives.” Another . . .

Healthcare Policy and Management
Pharmaceutical industry and healthcare
Original source
Mar 1, 2003¡The European Journal of Health Economics
57 cites
Pricing and reimbursement of drugs in Denmark

Kjeld Møller Pedersen

No abstract is available for this record.

Pharmaceutical Economics and Policy
Pharmaceutical industry and healthcare
Health Systems, Economic Evaluations, Quality of Life
Original source
Mar 1, 2002¡The European Journal of Health Economics
21 cites
Pricing and reimbursement of drugs in Sweden

Jonas Lundkvist

No abstract is available for this record.

Pharmaceutical Economics and Policy
Health Systems, Economic Evaluations, Quality of Life
Pharmaceutical industry and healthcare
Original source
Sep 1, 2000¡Journal of Healthcare Management
8 cites
The “Business”—or “Public Service”— of Healthcare

Walter J. Jones

From an international perspective, U.S. health policymaking is quite distinctive. Other economically advanced nations face the same problems of cost, access, and quality, but none use policymaking structures that resemble ours. To a great extent, the same American “exceptionalism” is evident when analyzing the values that motivate health policymakers. The American people have never truly resolved for themselves the fundamental question that must be considered when directing the objectives of health policies: Is American healthcare a business, a public service, or something in between? Most other wealthy nations have concluded that healthcare is primarily a public function, and have established systems with objectives directly or indirectly set by government and primarily paid for with tax dollars. In contrast, the United States maintains a mixed public-private sector system with no centralized policymaking or financing organization.1 Certainly, the resulting decentralization and flexibility in American health services has its advantages. On the other hand, many important financing and service questions are never resolved, since their solution would require ultimate priority setting by policymakers and, more broadly, by the American people. Irresolution as to whether healthcare is first and foremost a business or a public service is at the heart of major contemporary public policy problems. The following are two important examples. Academic health centers (AMCs) and the public goods of health education and research. Since the beginning of the 1980s, federal policymakers have generally encouraged competition between health providers, with the reasonable expectation that such competition would limit cost increases, encourage the development of a customer (or at least payer) service orientation, and lead to innovations in service delivery. This approach has had positive results in terms of reduced cost inflation and innovative service delivery methods. However, most health industry reform and innovation relies on certain “public goods” being present in the system as a whole. Just as all of us assume that we will have clean air and water as we live and do business, healthcare providers, when engaging in marketplace competition, assume that adequate numbers of trained health professionals will be available to staff their organizations. They also assume that a steady stream of technological advances will make state-of-the-art health services possible. Finally, since society seems to feel that all of its citizens deserve at least a survival level of health services, they have further assumed that other institutions, primarily public facilities, will provide services to those who cannot pay for them. But nongovernmental healthcare providers are not willing to directly pay much for these “public goods.” By and large, they simply expect that public institutions, particularly academic medical centers (AMCs), will provide these goods while they engage in the more lucrative business of market-based health services. However, AMCs have not been provided immunity from the cost pressures resulting from treating healthcare like a “business.” They are told to shape up and compete like other health providers in the marketplace, but they are also told to provide educated health professionals and research products to their competitors, and to take nonpaying patients off their competitors' hands. The funding that they need to do this cannot come primarily from their patients (customers), since a high proportion of them are uninsured and pay little or nothing for the health services. Other traditional sources of funding, including state appropriations, a “disproportionate share” from Medicare, and cost-shifting of uninsured care services to paying patients, are rapidly drying up. Employers paying for the care of their workforce will not pay for others who have no money, nor will they pay more for services because those providing them are also doing research and educating future health professionals. Therefore, most AMCs simply cannot compete in the marketplace. Even if the centers were run at peak efficiency (which they are not), they could not provide services at the prices offered by non-AMC hospitals, clinics, and physician group practices. Are AMCs businesses? If so, they probably cannot succeed as currently structured, because they are forced to provide unprofitable products like education, research, and “free” care. Are AMCs public services, providing unreimbursed health services, education, and research for the healthcare sector as a whole? If so, they cannot properly do their job if they are forced to compete with non-AMCs for survival, because they cannot meet marketplace prices without seriously damaging their educational, research, or service outreach missions. Medicare—A public institution to guarantee health equity for seniors, or a funding mechanism to provide marketplace choice for seniors? Viewed in terms of its original objectives—to reduce medical poverty for seniors—Medicare has been a major public policy success. In some ways it has been too successful. The open-ended commitment to services, along with the “graying of America” and healthcare technological advances, have led to major financing problems for Medicare. Quite properly, the federal government has begun to tighten Medicare's financial spigots. European nations, with publicly run and financed health systems, face the same problems, and can respond quite decisively. To elderly pensioners and their health service providers, European policymakers usually claim that they are doing as well as they can, and will provide more funding in the future, but must balance current public needs with available resources. No European would argue that this is ideal, but most would agree that public policymakers do have to make difficult tradeoffs.2 In the United States, however, healthcare providers are not charged with serving the national interest in carefully providing a public good. Rather, they are called upon to meet consumer demands in an evolving marketplace. Medicare is not a national health service. It is a complex system of writing and disbursing checks to providers for specified services to defined clients. On the one hand, the program is supposed to provide healthcare equality to seniors, so it has nationally defined benefits and prohibits balance billing. On the other hand, it does not take responsibility for providing the services themselves—that would be interfering with the marketplace. In fact, in recent years, Medicare Part C has been created to enhance the role of consumer choice in the marketplace. As Medicare has developed, this conflict—fulfilling a national mandate through the “business” of healthcare—has resulted in the creation of incredibly complicated payment guidelines. Providers have to devote large portions of their resources not to health services, but to Medicare “compliance.” They are also subject to progressively expansive federal mandates (such as the adoption of computerized patient records suitable for uploading into national databases for research purposes) that force them to restructure their organizations. Their consumers now supposedly have greater flexibility and choice, but that choice cannot entail paying more for any particular service; healthcare providers must follow detailed reimbursement schedules. At least, one supposes, U.S. providers can be thankful that they are in the “private” sector, unlike their unfortunate European counterparts, who have lost their independence to “big government” and “socialized medicine.” Is Medicare supposed to be a public commitment to healthcare equality for seniors? Then, as currently designed, it cannot guarantee equal services, since it lacks the direct controls over service provision found in (say) the National Health Service in the United Kingdom. Or is Medicare supposed to be a generous subsidy to the elderly so that they can obtain their healthcare in the marketplace? Then it is extremely inefficient, for it gives the money to the providers (along with damaging and cumbersome regulatory oversight) rather than empowering the senior “customers” to buy their own services (at whatever prices they negotiate) through direct cash payments or vouchers. The United States is now muddling through the unresolved conflict of health services as a business or as a public service. If AMCs are threatened with bankruptcy because of their divided missions, national and state governments will respond with arbitrary relaxation of the equally arbitrary cuts in disproportionate share, or provide some additional health research funding and student loans, which may tide the AMCs over until the next crisis. If Medicare rules (to preserve public control) lead to numerous federal indictments for reimbursement fraud (the providers trying to eke out every possible payment dollar to keep afloat in the competitive market), the larger providers will complain, and the federal government will relax its enforcement efforts, until another highly publicized crackdown is launched, and the cycle begins again. Perhaps the United States, with its wealth, will be able to keep muddling through indefinitely. If we keep slathering money around the healthcare system, taking it away here and putting it back there, perhaps we can keep believing that our healthcare system is both a business and a public service at the same time. We can avoid making fundamental decisions about the nature of healthcare. As long as we are willing to keep our wallets wide open, that is, and are not too fussy about the resulting disorder that keeps our healthcare managers in, as the Chinese would say, “interesting times.”

Pharmaceutical industry and healthcare
Healthcare Policy and Management
Primary Care and Health Outcomes
Original source
Sep 1, 2000¡Isis
86 cites
Visions of a Cure: Visualization, Clinical Trials, and Controversies in Cardiac Therapeutics, 1968-1998

David S. Jones

In the early 1970s physicians engaged in fierce debates over the most appropriate method of evaluating the efficacy of coronary artery bypass grafting (CABG). With millions of patients and billions of dollars at stake, CABG sparked fierce controversy. Skeptics demanded that randomized controlled trials (RCTs) be performed, while enthusiasts argued that they already had visual proof of CABG's efficacy. When RCTs appeared, they did not settle the controversy. Participants simply reasserted their preconceptions, defending a trial's strengths or exploiting its flaws. The debate centered on standards of knowledge for the evaluation of therapeutic efficacy. Specifically, cardiologists and cardiac surgeons struggled to assess the relevance of different measures of therapeutic success: physiological or clinical, visual or statistical. Many factors contributed to participants' decisions, including disciplinary affiliation, traditions of research, personal experience with angiography, and assessments of the history of cardiac therapeutics. Physicians had to decide whether angiography provided a meaningful representation of the disease and its treatment or whether demonstrations of therapeutic success could come only from long-term statistical evaluation of mortality data.

Open access
Health and Medical Research Impacts
Health Systems, Economic Evaluations, Quality of Life
Pharmaceutical industry and healthcare
Original source
Jan 1, 1987¡PubMed
4 cites
Industry distinctiveness: implications for strategic management in health care organizations.

Luke Rd, James W. Begun

The health care industry is characterized at its core by the requirement that the organization and financing of services recognize the concept of need for health care. This requirement is reflected in industry characteristics of market failure, professional dominance of physicians, and public concern with equal access to care. While market failure is decreasing as a result of the emergence of insurance companies as the "new consumers" of health services, physician dominance and concerns for access continue to be strong. These characteristics mean that successful health care organizations will be local-market focused, decentralized, and tied to community cultures. With regard to training of health services administrators, education should be strengthened in the area of strategy development, with appropriate recognition given to the distinctiveness of the health care industry.

Pharmaceutical industry and healthcare
Original source
Dec 1, 1986¡PubMed
2 cites
Physician-hospital joint venture addresses mutual needs.

Gleason Sc, Sullivan Pc

Establishing a system of family practice clinics with physicians from its medical staff enabled Mercy Hospital Medical Center, Des Moines, IA, not only to meet consumers' changing needs and wants but also to develop a long-term strategy for survival. The joint venture, which has grown to 9 clinics and 30 physicians since its inception in 1983, does not restrict the hospital from entering into similar relationships with other physician groups. Neither does it restrict physicians from entering new arrangements or using other hospitals. Each clinic operates quasi-autonomously in serving its own patients, and issues such as hiring, firing, hours of operation, and local public relations are handled in a decentralized manner. Other matters--insurance coverage, marketing programs, accounting and data processing systems--are standardized throughout the organization. Challenges involved in undertaking such a project include overcoming resistance from employees, building public awareness of the project, and creating an open, trusting relationship between physicians and administrators. It is particularly important to foster the support of physicians "outside" the partnership and to include those who remain in private practice in marketing efforts.

Healthcare Policy and Management
Primary Care and Health Outcomes
Pharmaceutical industry and healthcare
Original source